Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. Compared with opioids, which bind to µ-opioid receptors during the central anxious process, conolidine modulates alternate molecular targets. A Science Developments study found that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability... https://keikok541ebh2.azuria-wiki.com/user